RSS   Newsletter   Contact   Advertise with us

AstraZeneca Q1 net profit down, core EPS up

Staff Writer | April 27, 2017
AstraZeneca reported that its first-quarter profit before tax declined to $582 million from last year's $723 million last year.
AstraZeneca   Core earnings per share increased 4% to $0.99
Profit attributable to owners of the Parent was $537 million, down from $646 million a year ago. Earnings per share dropped 17 percent to $0.42 from $0.51 a year ago.

Core earnings per share increased 4% to $0.99.

Total revenue declined 12 percent to $5.41 billion from last year's $6.12 billion. At constant rates, revenues fell 10 percent.

The Product Sales declined as performance mainly reflected the residual impact of the US Crestor patent expiry.

Further, the company confirmed its financial guidance for 2017. The company continues to expect total revenue to decline a low to mid single-digit percentage and core earnings per share to decline a low to mid teens percentage for the full year.